SMARCA4 and prostate neoplasm: Valdman et al. performed a complete mutational analysis of all 37 BRG1 exons in 21 prostate tumors and found a complete lack of mutations [24], although BRG1 loss ranges from ~15% to 50% by IHC [59–61].